miR-221/222-3p作为心力衰竭中的潜在循环因子,刺激癌症进展
Rongfeng Xu1, Jiaqi Guo2, Zhenjun Ji1
1Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, China.
Frontiers in oncology
|January 28, 2026
概括
微RNA-221/222-3p在心力衰竭 (HF) 中被上调,并促进癌症的发展. 抑制这种微RNA可以逆转由HF血清诱导的癌细胞增殖,这表明HF和癌症之间存在联系.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 流行病学研究将心力衰竭 (HF) 与癌症发病率增加联系起来.
- 通过HF促进癌症的机制在很大程度上是未知的.
- 研究微RNA-221/222-3p失调在高频率相关癌症发展中的作用.
研究的目的:
- 澄清心力衰竭 (HF) 中miR-221/222-3p失调在促进癌症中的潜在作用.
- 通过生物信息学和体外验证,探索HF,miR-221/222-3p和癌症之间的关联.
主要方法:
- 生物信息学工具的全面应用 (例如,TargetScanHuman,miRNET,STRING,GEPIA). 这是一个非常重要的技术.
- 在体外研究涉及冠状动脉疾病 (CAD) 患者的血清,有或没有HF添加到HT-29结肠癌细胞.
- 细胞增殖 (EdU,CCK8) 和PCNA水平的评估;测量miR-221/222-3p表达 (qRT-PCR).
主要成果:
- miR-221/222-3p广泛分布,包括心脏,与高频率相关.
- 生物信息学分析揭示了与癌症相关的功能和常见恶性瘤的关键调节作用.
- miR-221/222-3p在HF患者血清中升高,并促进HT-29细胞增殖,抑制剂可以逆转效果.
结论:
- miR-221/222-3p可能是心力衰竭 (HF) 和癌症之间的关键联系.
- 在HF中对miR-221/222-3p的升调有助于促进癌症.
- 向miR-221/222-3p可能是对HF相关癌症的潜在治疗策略.
相关概念视频
01:29Heart Failure II: Pathophysiology
872
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
872
01:17Pathophysiology of Heart Failure
3.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.5K
01:27Heart Failure I: Introduction
847
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
847
01:22Heart Failure VI: Adjunct Therapies
314
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
314
01:22Heart Failure Drugs: Diuretics
948
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
948
01:30Heart Failure V: Medical Management
272
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
272